SCHEMBL5363355

SCHEMBL5363355

CNS(=O)(=O)c1ccc2c(c1)C(=Cc1ccc(O)cc1OC)C(=O)N2

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SYK P43405 8/20 0.58
NTRK1 P04629 4/20 0.58
NTRK3 Q16288 3/20 0.58
NTRK2 Q16620 3/20 0.58
FCER2 P06734 2/20 0.58
MDM2 Q00987 2/20 0.52
SRC P12931 3/20 0.51
CDK2 P24941 2/20 0.49
RET P07949 1/20 0.48
KDR P35968 2/20 0.48
PTPN1 P18031 1/20 0.46
NPC1 O15118 1/20 0.46
LCK P06239 1/20 0.45
FYN P06241 1/20 0.45
YES1 P07947 1/20 0.45
PDGFRB P09619 1/20 0.45
FGFR1 P11362 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5365612 0.89 SYK (0.69) SYKNTRK1NTRK3NTRK2FCER2
SCHEMBL5367229 0.87 NTRK1 (0.55) SYKNTRK1NTRK3NTRK2FCER2
SCHEMBL5362886 0.87 SYK (0.61) SYKNTRK1NTRK3NTRK2FCER2
SCHEMBL7131130 0.86 NPC1 (0.63) SYKNTRK1NTRK3NTRK2FCER2
SCHEMBL5367174 0.86 SYK (0.58) SYKNTRK1NTRK3NTRK2FCER2
SCHEMBL5374277 0.86 SYK (0.68) SYKNTRK1NTRK3NTRK2FCER2
SCHEMBL7137047 0.85 SRC (0.52) SYKNTRK1NTRK3NTRK2FCER2
SCHEMBL5369883 0.85 NTRK1 (0.55) SYKNTRK1NTRK3NTRK2FCER2
SCHEMBL5369712 0.85 SYK (0.57) SYKNTRK1NTRK3NTRK2FCER2
SCHEMBL5367549 0.84 SYK (0.58) SYKNTRK1NTRK3NTRK2FCER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK SYK 54/4885NTRK1 223/4885NTRK3 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.